Stock Scorer

Zivo Bioscience, Inc. (ZIVO)

Zivo Bioscience, Inc. reported revenue of 65.6K USD for the quarter ending 30 September 2025, up 108.3% from 31.5K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q3 '25 · ending 30 September 2025 65.6K +108.3%
Gross Profit Q3 '25 · ending 30 September 2025 21.3K +125.3%
Operating Income Q3 '25 · ending 30 September 2025 -1M —
Net Income Q3 '25 · ending 30 September 2025 -1M —
Cost of Revenue Q3 '25 · ending 30 September 2025 44.3K +101.1%
Operating Cash Flow Q3 '25 · ending 30 September 2025 -266.6K —
Free Cash Flow Q3 '13 · ending 30 September 2013 -783.5K —
Shares Outstanding Q3 '25 · ending 30 September 2025 3.8M +28.9%
EPS Q3 '25 · ending 30 September 2025 -2.18 -631.7%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20242024-12-31 157.2K-13.4M-13.4M—
20232023-12-31 27.6K-7.3M-7.8M—
20222022-12-31 0-8.7M-8.7M—
20212021-12-31 0-8.6M-8.8M—
20202020-12-31 20K-8.6M-9.1M—
20192019-12-31 0-8.4M-11.5M—
20182018-12-31 0-6.1M-14.6M—
20172017-12-31 0-6.3M-10M—
20162016-12-31 0-3.5M-6.1M—
20152015-12-31 0-3.1M-5.8M—

Every period

Revenue Quarterly

PeriodEndingRevenue
Q3 '252025-09-3065.6K
Q2 '252025-06-3053.4K
Q1 '252025-03-310
Q4 '242024-12-3190K
Q3 '242024-09-3031.5K
Q2 '242024-06-300
Q1 '242024-03-3135.7K
Q4 '232023-12-3111.8K
Q3 '232023-09-3011.8K
Q2 '232023-06-304K
Q1 '232023-03-310
Q4 '222022-12-310
Q3 '222022-09-300
Q2 '222022-06-300
Q1 '222022-03-310
Q4 '212021-12-310
Q3 '212021-09-300
Q2 '212021-06-300
Q1 '212021-03-310
Q4 '202020-12-310

Gross Profit Quarterly

PeriodEndingGross Profit
Q3 '252025-09-3021.3K
Q2 '252025-06-3017.9K
Q1 '252025-03-310
Q4 '242024-12-3127K
Q3 '242024-09-309.4K
Q2 '242024-06-300
Q1 '242024-03-3112.5K
Q4 '232023-12-314.1K
Q3 '232023-09-304.1K
Q2 '232023-06-303.3K
Q1 '232023-03-310
Q4 '222022-12-310
Q3 '222022-09-300
Q2 '222022-06-300
Q1 '222022-03-310

Operating Income Quarterly

PeriodEndingOperating Income
Q3 '252025-09-30-1M
Q2 '252025-06-30-1.6M
Q1 '252025-03-31-4.2M
Q4 '242024-12-31-1.6M
Q3 '242024-09-30-2.3M
Q2 '242024-06-30-8.2M
Q1 '242024-03-31-1.3M
Q4 '232023-12-31-1.9M
Q3 '232023-09-30-1.6M
Q2 '232023-06-30-1.8M
Q1 '232023-03-31-2M
Q4 '222022-12-31-2.6M
Q3 '222022-09-30-2M
Q2 '222022-06-30-2.1M
Q1 '222022-03-31-2M
Q4 '212021-12-31-3.3M
Q3 '212021-09-30-1.7M
Q2 '212021-06-30-1.7M
Q1 '212021-03-31-2.1M
Q4 '202020-12-31-1.8M

Net Income Quarterly

PeriodEndingNet Income
Q3 '252025-09-30-1M
Q2 '252025-06-30-1.6M
Q1 '252025-03-31-4.2M
Q4 '242024-12-31-1.6M
Q3 '242024-09-30-2.3M
Q2 '242024-06-30-8.2M
Q1 '242024-03-31-1.3M
Q4 '232023-12-31-1.9M
Q3 '232023-09-30-1.8M
Q2 '232023-06-30-2.1M
Q1 '232023-03-31-2M
Q4 '222022-12-31-2.6M
Q3 '222022-09-30-2M
Q2 '222022-06-30-2.1M
Q1 '222022-03-31-2M
Q4 '212021-12-31-3.3M
Q3 '212021-09-30-1.6M
Q2 '212021-06-30-1.8M
Q1 '212021-03-31-2.2M
Q4 '202020-12-31-1.9M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q3 '252025-09-3044.3K
Q2 '252025-06-3035.5K
Q1 '252025-03-310
Q4 '242024-12-3163K
Q3 '242024-09-3022.1K
Q2 '242024-06-300
Q1 '242024-03-3123.2K
Q4 '232023-12-317.7K
Q3 '232023-09-307.7K
Q2 '232023-06-30701
Q1 '232023-03-310
Q4 '222022-12-310
Q3 '222022-09-300
Q2 '222022-06-300
Q1 '222022-03-310

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q3 '252025-09-30-266.6K
Q2 '252025-06-30-476.4K
Q1 '252025-03-31-1.4M
Q4 '242024-12-31-905.7K
Q3 '242024-09-30-1.1M
Q2 '242024-06-30-623.7K
Q1 '242024-03-31-1.7M
Q4 '232023-12-31-715.7K
Q3 '232023-09-30-2M
Q2 '232023-06-30-985.7K
Q1 '232023-03-31-2.1M
Q4 '222022-12-31-1.4M
Q3 '222022-09-30-1.5M
Q2 '222022-06-30-1.3M
Q1 '222022-03-31-2.9M
Q4 '212021-12-31-1.9M
Q3 '212021-09-30-1.8M
Q2 '212021-06-30-2M
Q1 '212021-03-31-1.1M
Q4 '202020-12-31-901.5K

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q3 '132013-09-30-783.5K
Q4 '122012-12-31-356.7K
Q3 '122012-09-30-468.6K
Q2 '122012-06-30-417.3K
Q1 '122012-03-31-534.2K
Q1 '122012-03-31-534.2K
Q4 '112011-12-31-523.7K
Q3 '112011-09-30-254.4K
Q2 '112011-06-30-196.2K
Q1 '112011-03-31-324.5K
Q3 '102010-09-30-307.7K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q3 '252025-09-303.8M
Q2 '252025-06-303.8M
Q1 '252025-03-313.8M
Q3 '242024-09-303.4M
Q2 '242024-06-303M
Q1 '242024-03-312.7M
Q2 '152015-06-30130.4M
Q1 '152015-03-31129.6M
Q3 '142014-09-30127.9M
Q2 '142014-06-30124.7M
Q1 '142014-03-31154M
Q3 '132013-09-30110.4M
Q2 '132013-06-30106.8M
Q1 '132013-03-31105.3M
Q3 '112011-09-3097.5M
Q2 '112011-06-3095.6M
Q3 '102010-09-3089.6M
Q2 '102010-06-3086.9M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q3 '252025-09-30-2.18
Q2 '252025-06-30-2.58
Q1 '252025-03-31-4.93
Q4 '242024-12-31-4.28
Q3 '212021-09-300.41
Q2 '212021-06-30-0.07
Q1 '212021-03-31-0.02
Q4 '202020-12-31-0.02
Q3 '202020-09-30-0.94
Q2 '202020-06-30-0.26
Q1 '202020-03-31-0.04
Q4 '192019-12-31-0.05
Q3 '192019-09-30-0.05
Q2 '192019-06-30-0.07
Q1 '192019-03-31-0.08
Q4 '182018-12-31-0.09
Q3 '182018-09-30-0.11
Q2 '182018-06-30-0.10
Q1 '182018-03-31-0.09
Q4 '172017-12-31-0.07